Dupilumab cuts exacerbations in late-onset asthma

(HealthDay)—Dupilumab is associated with significantly reduced severe exacerbation rates in patients with late-onset asthma with or without fixed airway obstruction, according to a study presented at

Updated on: April 15,2024 18

Dupilumab cuts exacerbations in late-onset asthma

(HealthDay)—Dupilumab is associated with significantly reduced severe exacerbation rates in patients with late-onset asthma with or without fixed airway obstruction, according to a study presented at

Updated on:April 15,2024 18

FDA approves 1st drug for moderate and severe eczema cases

by Linda A. JohnsonThis image provided by Sanofi shows a box containing two single-dose pre-filled syringes of the drug Dupixent. On Tuesday, March 28, 2017, the Food and Drug Administration approved

Updated on: April 15,2024 20

FDA approves 1st drug for moderate and severe eczema cases

by Linda A. JohnsonThis image provided by Sanofi shows a box containing two single-dose pre-filled syringes of the drug Dupixent. On Tuesday, March 28, 2017, the Food and Drug Administration approved

Updated on:April 15,2024 20

New vaccine protects from widespread, costly infection, mice study shows

by American Society for MicrobiologyCredit: CC0 Public DomainA newly developed experimental vaccine was more than eighty percent effective in protecting mice from succumbing toStaphylococcu

Updated on: May 08,2024 6

New vaccine protects from widespread, costly infection, mice study shows

by American Society for MicrobiologyCredit: CC0 Public DomainA newly developed experimental vaccine was more than eighty percent effective in protecting mice from succumbing toStaphylococcu

Updated on:May 08,2024 6

SARS-CoV-2 disrupts timing of immune response

by Charité - Universitätsmedizin BerlinAssay to detect the biochemical messenger TGFβ (COVID-19 research). Credit: Charité | Arne SattlerOnce an infection is under control, the body normally uses

Updated on: April 22,2024 17

SARS-CoV-2 disrupts timing of immune response

by Charité - Universitätsmedizin BerlinAssay to detect the biochemical messenger TGFβ (COVID-19 research). Credit: Charité | Arne SattlerOnce an infection is under control, the body normally uses

Updated on:April 22,2024 17

A bacterial toxin turning cells into swiss cheese

by Kanazawa UniversityResearchers from Kanazawa University developed a novel tool to study how the innate immune system fights bacterial toxins. They purified the pore-forming toxin Monalysin fro

Updated on: May 05,2024 20

A bacterial toxin turning cells into swiss cheese

by Kanazawa UniversityResearchers from Kanazawa University developed a novel tool to study how the innate immune system fights bacterial toxins. They purified the pore-forming toxin Monalysin fro

Updated on:May 05,2024 20

CAR T cells suppress GI solid tumor cells, without toxicity to healthy tissue, in preclinical research

by University of PennsylvaniaCDH17 CARTs attack tumor but spare normal tissue. Credit: Penn MedicineChimeric antigen receptor (CAR) T cells can be remarkably effective in treating leukemias and l

Updated on: April 09,2024 16

CAR T cells suppress GI solid tumor cells, without toxicity to healthy tissue, in preclinical research

by University of PennsylvaniaCDH17 CARTs attack tumor but spare normal tissue. Credit: Penn MedicineChimeric antigen receptor (CAR) T cells can be remarkably effective in treating leukemias and l

Updated on:April 09,2024 16

Aerobic exercise may cut fatigue in rheumatoid arthritis

(HealthDay)—Aerobic land-based exercise may be helpful in treating fatigue in patients with rheumatoid arthritis (RA), according to a meta-analysis published in the August issue ofArthritis Care

Updated on: March 24,2024 13

Aerobic exercise may cut fatigue in rheumatoid arthritis

(HealthDay)—Aerobic land-based exercise may be helpful in treating fatigue in patients with rheumatoid arthritis (RA), according to a meta-analysis published in the August issue ofArthritis Care

Updated on:March 24,2024 13

Curbing blood cancers by teaching immune cells to kill mutant stem cells

by Nancy Fliesler,Children's Hospital BostonROS and TLR3 signaling mediates the "eat-me" and "don't eat me" signals that determine stem cell clonal selection by macro

Updated on: October 24,2024 0

Curbing blood cancers by teaching immune cells to kill mutant stem cells

by Nancy Fliesler,Children's Hospital BostonROS and TLR3 signaling mediates the "eat-me" and "don't eat me" signals that determine stem cell clonal selection by macro

Updated on:October 24,2024 0

A key gene modifies regulatory T cells to fine-tune the immune response

by Salk InstituteA histology image showing inflammation in colon epithelium. Weakening of regulatory T cell function induces infiltration of immune cells (small blue dots) into colon epithelium (

Updated on: May 07,2024 18

A key gene modifies regulatory T cells to fine-tune the immune response

by Salk InstituteA histology image showing inflammation in colon epithelium. Weakening of regulatory T cell function induces infiltration of immune cells (small blue dots) into colon epithelium (

Updated on:May 07,2024 18

How lockdown impacts those with bone, joint and muscle pain

by University of East AngliaCredit: CC0 Public DomainUniversity of East Anglia researchers are launching a new study to see how COVID-19 and lockdown are affecting people with bone, joint and mus

Updated on: June 01,2024 8

How lockdown impacts those with bone, joint and muscle pain

by University of East AngliaCredit: CC0 Public DomainUniversity of East Anglia researchers are launching a new study to see how COVID-19 and lockdown are affecting people with bone, joint and mus

Updated on:June 01,2024 8

CVD risk factors tied to disease activity, disability in RA

(HealthDay)—Cardiovascular disease (CVD) risk factors alone, or in combination, are associated with higher disease activity and disability in rheumatoid arthritis (RA), according to a study recently p

Updated on: June 01,2024 3

CVD risk factors tied to disease activity, disability in RA

(HealthDay)—Cardiovascular disease (CVD) risk factors alone, or in combination, are associated with higher disease activity and disability in rheumatoid arthritis (RA), according to a study recently p

Updated on:June 01,2024 3

New Anti-inflammatory Therapy Strategy: Targeted Inhibition of Inflammation by IDO and Galectin-3 Fusion

Updated on: September 21,2024 0

New Anti-inflammatory Therapy Strategy: Targeted Inhibition of Inflammation by IDO and Galectin-3 Fusion

Updated on:September 21,2024 0